Journal September 16, 2026 6 min read

Semaglutide: What It Is Studied Alongside

Semaglutide is a long-acting GLP-1 receptor agonist. Research studies pair it with other compounds, comparators, and clinical contexts — here is what the evidence shows.

peptides-pro Editorial

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is studied as a single agent and alongside other interventions, comparators, and clinical contexts. The evidence block for this page does not provide sequence, formula, or molecular weight identifiers; it identifies semaglutide by its class and by the receptor family its activity centres on. The work described here centres on the GLP-1 receptor and its downstream metabolic and neuroendocrine effects.

Across the studies cited, semaglutide appears in several distinct research roles: as an adjunct to standard care in postpartum individuals with recent gestational diabetes [1], as an adjunct to antipsychotic treatment in patients with schizophrenia and metabolic syndrome [2], as a background therapy in trials of muscle-preservation compounds [3], as a comparator in a switch study to zovaglutide [4], as a dose-ranging agent in alcohol use disorder with obesity [5], as an active comparator to zenagamtide [6], as an early re-initiation strategy after sleeve gastrectomy in youth [7], and as an addition to structured lifestyle support in postmenopausal breast cancer survivors on aromatase inhibitors [8].

Research Studies

Semaglutide and postpartum cardiometabolic risk after gestational diabetes

A randomized clinical trial is evaluating immediate postpartum semaglutide following a pregnancy complicated by gestational diabetes mellitus (GDM). The study is an effectiveness-implementation Hybrid Type 1 design. A total of 226 postpartum individuals with recent GDM are randomized 1:1 to semaglutide or standard postpartum care for a 6-month active treatment phase. The primary effectiveness outcome is development of metabolic syndrome, assessed at 6 months postpartum. Participants then enter a 6-month maintenance phase, during which semaglutide continuation, discontinuation, or initiation reflects patient and clinician decisions [1].

Semaglutide and cardiometabolic profile in schizophrenia with metabolic syndrome

Patients with schizophrenia on second-generation antipsychotics have a high burden of metabolic syndrome and elevated cardiovascular risk, with few effective treatment options. A multicentre, double-blind, placebo-controlled randomized trial is evaluating whether adjunctive oral semaglutide 3 mg once daily, added to treatment as usual, reduces 10-year cardiovascular risk (QRISK3) and improves insulin resistance, lipids, weight, and metabolic biomarkers over 24 weeks compared with placebo, while confirming psychiatric safety and tolerability [2].

Semaglutide and muscle preservation with HMB plus vitamin D in older adults

A randomized, double-blind, placebo-controlled trial is evaluating whether daily calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB) plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes who are newly starting semaglutide as part of usual clinical care. Participants receive calcium-HMB plus vitamin D3 or matching placebo for approximately 6 months. The primary outcome is change in appendicular lean mass measured by dual-energy X-ray absorptiometry from baseline to month 6. Secondary assessments include body composition, muscle strength, physical performance, gait, physical activity, and resting metabolic rate [3].

Semaglutide and switching to zovaglutide in adults with obesity

A study is evaluating the safety and tolerability of continuing treatment with zovaglutide injection following titration to 2.4 mg semaglutide injection in adult participants with obesity. The main purpose is to assess safety and tolerability of the switch [4].

Semaglutide and dose effects on alcohol craving and stress hormones in alcohol use disorder with obesity

A study is examining two doses of semaglutide, 1.0 mg and 2.0 mg, versus placebo in patients with alcohol use disorder (AUD) and obesity (Ob) to assess whether these doses improve alcohol craving, stress, and alcohol use outcomes [5].

Semaglutide and zenagamtide in excess body weight

A study is investigating how well zenagamtide helps people with excess body weight lose weight compared to semaglutide. The purpose is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide [6].

Semaglutide and early reinitiation after sleeve gastrectomy in youth

A Phase 3a, randomized, parallel-controlled trial is comparing early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial involves 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery. Participants are randomized to either semaglutide 2.4 mg weekly or standard care for 24 months. Outcomes are assessed at 1 month, day of surgery, and 1, 3, 6, 9, 12, 18, and 24 months postoperatively. The hypothesis is that early re-initiation of semaglutide will be safe [7].

Semaglutide and structured lifestyle support in postmenopausal breast cancer survivors on aromatase inhibitors

A phase IV trial is studying whether adding semaglutide to structured lifestyle support improves heart and blood vessel health in postmenopausal obese breast cancer survivors (BCS) who are taking an aromatase inhibitor. In this population, obesity raises the risk of heart and blood vessel problems. The structured lifestyle support includes counseling on nutrition and physical activity with specific recommendations for individuals to follow [8].

Semaglutide and analytical detection in formulations and biological matrices

A comprehensive review reports that semaglutide is a potent long-acting glucagon-like peptide-1 receptor agonist with therapeutic efficacy for type 2 diabetes and obesity. Because of its widespread clinical use, there is increasing demand for analytical techniques to identify semaglutide in pharmaceutical formulations and biological matrices [9].

Semaglutide and treatment patterns in community pharmacy settings

A cross-sectional survey investigated semaglutide treatment patterns among Danish adult users for weight management. The survey was conducted across 28 Danish community pharmacies between March and May 2025. The study reports on treatment patterns and experienced effects among adult users [10].

Semaglutide and neuropsychiatric outcomes compared with other GLP-1 receptor agonists

A study examined neuropsychiatric safety concerns, including depression and suicidal ideation, that have emerged during the expanding clinical use of incretin-based therapies for type 2 diabetes mellitus and obesity. The study reports that whether risks differ across successive generations of incretin-based therapies remains uncertain [11].

Semaglutide and gallbladder-related adverse events

A pooled analysis of placebo-controlled STEP trials reports on gallbladder-related adverse events with semaglutide 2.4 mg [12].

If you are reading this for personal health reasons

The material described here is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.